Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets […]
Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients […]
Roche Launches Comprehensive Genomic Profiling Kit to Expand Access to Personalised Cancer Research
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has launched the AVENIO Tumor Tissue […]
Immunotherapy Approved for Some People with Oesophageal Cancer on NHS in England
The National Institute for Health and Care Excellence (NICE) has recommended the use of the […]
Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies
Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat […]
Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer
Novartis today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising […]
Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment
Aichi Cancer Center and Fujitsu Limited today announced the development of an AI solution able […]
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement […]
Oncology is a Major Focus for Many AI Drug Discovery Companies, Reports IDTechEx
The application of artificial intelligence (AI) in the drug discovery process is promising to drastically […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more